#AS­CO22: As it dodges a takeover bid, Zymeworks wants what Dai­ichi Sankyo got: a mas­sive Big Phar­ma part­ner

CHICA­GO — The Dai­ichi Sankyo sto­ry made waves Sun­day at the an­nu­al AS­CO meet­ing in Chica­go, as En­her­tu po­ten­tial­ly dis­rupt­ed the breast can­cer land­scape by …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER